---
title: "73 Series B Biotech Investors (Nov 2026)"
last_updated: "2026-11-07"
rows: "73"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/series-b-biotech-investors/"
---

# 73 Series B biotech investors

We list 73 Series B biotech investors as of November 2026: 34 have an SEC filing on file and 39 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (11), New York (7) and Massachusetts (3).

- 73 investors
- 39 with a fund filing or dated deal in the last 12 months
- $75M median fund size on file (SEC Form D, 21 firms)
- 385 named decision-makers on file

## First 25 of 73 Series B biotech investors

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Claret Capital Partners | Venture debt | London, United Kingdom | Series B, Growth, Late stage | Biotech, Healthtech, Climate Tech, SaaS | New deal, Oct 2026 | €575M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/claret-capital-partners/ |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hbm-partners-ag/ |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/andera-partners/ |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/bgf/ |
| Hadean Ventures | VC firm | Norway | Seed, Series A, Series B | Biotech, Healthtech, Medtech | New deal, Sep 2026 | €230M (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/hadean-ventures-as/ |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/madrona/ |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/bison-ventures/ |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/sofinnova-partners/ |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/cornucopian-capital/ |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/wellington-partners/ |
| Calculus VC | VC firm | Foster City, CA | Series A, Series B | Biotech, AI, Deep Tech, Healthtech | New deal, Aug 2026 | $1M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/calculus-vc/ |
| How Women Invest | VC firm | Oakland, CA | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, B2B | New fund, Sep 2026 | $12M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/how-women-invest/ |
| Arboretum Ventures | VC firm | Ann Arbor, MI | Series A, Series B | Biotech, Healthtech, Medtech | Portfolio news, Mar 2026 | $250M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/arboretum-ventures/ |
| Cultivation Capital | VC firm | St. Louis, MO | Seed, Series A, Series B | Biotech, Healthtech, SaaS, Agritech | New fund, Sep 2026 | $100M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/cultivation-capital/ |
| Apple Tree Venture | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | Portfolio news, Sep 2025 | $3.5B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/apple-tree-venture/ |
| Industrifonden | VC firm | Stockholm, Sweden | Seed, Series A, Series B, Growth | Biotech, Healthtech, Deep Tech, Climate Tech | Portfolio news, Oct 2026 |  | 2026-11-07 | https://theinvestordatabase.com/investors/industrifonden/ |
| TVM Capital Life Science | VC firm | Munich, Germany | Seed, Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, Sep 2026 |  | 2026-11-07 | https://theinvestordatabase.com/investors/tvm-capital-life-science/ |
| Overlap Holdings | VC firm | Hicksville, NY | Seed, Series A, Series B | Biotech, AI, Energy, Climate Tech | New fund, Oct 2026 | $16M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/overlap-holdings/ |
| Frazier Life Sciences | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | New fund, Mar 2025 | $7.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/frazier-life-sciences/ |
| RA Capital | VC firm | Boston, MA | Pre-seed, Seed, Series A, Series B, Growth, Any stage | Biotech, Healthtech, Climate Tech, Energy | New deal, Aug 2025 | $881M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/ra-capital/ |
| Bramalea Partners | VC firm | Medfield, MA | Series B, Growth | Biotech, Healthtech, AI, Fintech | Portfolio news, Mar 2026 | $78M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/bramalea-partners/ |
| Gilde Healthcare | Fund manager | Utrecht, Netherlands | Series A, Series B, Growth | Biotech, Healthtech, Medtech, Climate Tech | New fund, Feb 2026 | €3.0B (own site) | 2026-11-07 | https://theinvestordatabase.com/investors/gilde-healthcare-partners-b-v/ |
| Star51 Capital | VC firm | New York, NY | Seed, Series A, Series B, Growth | Biotech, Healthtech, AI, Robotics | New deal, Sep 2026 |  | 2026-11-04 | https://theinvestordatabase.com/investors/star51-capital/ |
| FCA Venture Management Group | VC firm | Nashville, TN | Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | Portfolio news, May 2026 | $58M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/fca-venture-management-group/ |
| Oxford Science Enterprises | VC firm | Oxford, United Kingdom | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech, AI, Deep Tech | Portfolio news, Mar 2026 | £1.4B (own site) | 2026-11-04 | https://theinvestordatabase.com/investors/oxford-science-enterprises/ |

You are seeing 25 of 73. The full list adds 48 more investors and 385 named decision-makers.

Get all 73 investors and 385 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/series-b-biotech-investors
This page: https://theinvestordatabase.com/lists/series-b-biotech-investors/

## Method and limits
- Source: 34 of the 73 rows carry an SEC filing (Form D or Form ADV). All 73 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series B.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series B is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 73 rows: stage 73, sector 73, fund size 51, website 73. In the paid file: named decision-makers on 69 rows, firm email on 36, LinkedIn page on 50, check size on 14.

## Questions
### How many Series B biotech investors are there?
We list 73 as of November 2026. 39 of the 73 have a fund filing or a dated deal in the last 12 months.

### Which Series B biotech investors raised a new fund in the last 12 months?
14 of the 73 have a fund filing dated in the last 12 months. The most recent on this list are Bison Ventures (Oct 2026), Overlap Holdings (Oct 2026) and Cultivation Capital (Sep 2026).

### What is the typical fund size of Series B biotech investors?
The median fund size on file for this list is $75M, across the 21 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 52 do not disclose a size there.

### How do I contact Series B biotech investors?
The paid file holds 385 named decision-makers across 69 of these 73 and a firm email for 36. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on Series B biotech investors come from?
34 of the 73 rows have an SEC filing on file (Form D or Form ADV) and 39 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.